AFFYMAX APPOINTS JIM YOUNG SENIOR VICE PRESIDENT FOR CORPORATE DEVELOPMENT
AFFYMAX APPOINTS JIM YOUNG SENIOR VICE PRESIDENT
FOR CORPORATE DEVELOPMENT
AMSTERDAM, The Netherlands, May 7 /PRNewswire/ -- Affymax N.V. (NASDAQ: AFMXF) announced today the appointment of James W. Young, Ph.D., managing director and senior vice president for corporate development of Affymax Technologies N.V. In this capacity, Young will be responsible for business development, evaluating and acquiring new technologies and establishing Affymax's pharmaceutical operations.
Young joins Affymax from Sepracor Inc., where he was vice president and general manager of Sepracor's Pharmaceuticals Division. Prior to joining Sepracor, Young was vice president of research at Zoecon Corp. which was acquired by Sandoz Crop Protection Crop. during his tenure. During his 16-year career at Zoecon and Sandoz, Young held leadership roles in research management, formulation chemistry, regulatory affairs and molecular biology. He has a Ph.D. in chemistry from Cornell University.
"Dr. Young's business development and pharmaceutical operations leadership will be important as we seek to capitalize, as rapidly as possible, on our innovative drug discovery technologies," said John D. Diekman, Ph.D., president of Affymax.
Affymax, a Netherlands Corporation, is developing new technologidevelop drugs independently and in collaboration with established pharmaceutical companies. The majority of the company's research and development activities are performed by it wholly owned subsidiary, Affymax Research Institute, located in Palo Alto, Calif.
/CONTACT: David B. Singer of Affymax, 415-496-2300/
(AFMXF) CO: Affymax ST: California IN: MTC SU: PER
MC-MM -- SJ001 -- 7455 05/07/92 09:05 EDT